Lazard Asset Management
IPXL

Lazard Asset Management’s Impax Laboratories, Inc. IPXL Stock Holding History

Lazard Asset Management’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50,000
Closed -$1.01M – 1137
2017
Q3 		$1.01M Buy
+50,000
New +$956K ﹤0.01% 676

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TG
TCW Group Los Angeles, California $13.3B AUM 34.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lazard Asset Management's IPXL Position: Q4 2017 in Review

Lazard Asset Management sold out of Impax Laboratories, Inc. (IPXL) in Q4 2017, closing a stake of 50,000 shares — an estimated $1.01M sold.

Lazard Asset Management first reported a position in IPXL in Q3 2017 and held it in 1 quarter. The position peaked at $1.01M in Q3 2017. 200 funds tracked by Wall St. Rank hold IPXL as of Q4 2017.

  • Lazard Asset Management reported no remaining Impax Laboratories, Inc. position as of Q4 2017 after selling out during the quarter.
  • Lazard Asset Management sold 50,000 Impax Laboratories, Inc. shares in Q4 2017, an estimated $1.01M.
  • Lazard Asset Management first reported a position in Impax Laboratories, Inc. in Q3 2017 and held it in 1 quarter.
  • Lazard Asset Management's Impax Laboratories, Inc. position peaked at $1.01M in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2017.

Based on Lazard Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.